ST. LOUIS, Oct. 16, 2014 /PRNewswire/ -- BioReliance(®) (www.bioreliance.com), Sigma-Aldrich Corporation's (NASDAQ: SIAL) biologics and early-development services business under SAFC(®) Commercial (www.sigmaaldrich.com/safc), has introduced select in vitro ADME (absorption, distribution, metabolism and excretion) and toxicology testing services for pharmaceutical, chemical and industrial consumer products to its service ... read more
ST. LOUIS, Sept. 18, 2014 /PRNewswire/ -- Sigma-Aldrich Corporation (Nasdaq: SIAL) announced today it has entered into a new gene editing partnership with the University of Michigan (U-M) Medical School's Vector Core. Under the partnership, Sigma-Aldrich will provide the Vector Core with Sigma CRISPR technology, experimental ... read more
SAINT LOUIS, Sept. 10, 2014 /PRNewswire/ -- Sigma-Aldrich Corporation (NASDAQ: SIAL) is pleased to announce that its Cerilliant(®) branded products are now available through Sigma-Aldrich Canada.
Service through Sigma-Aldrich Canada allows the Company's Canadian customers to readily obtain Cerilliant products domestically, in local currency and language - ... read more
ST. LOUIS, July 24, 2014 /PRNewswire/ --
Q2 2014 Results (all percentage changes are against the same period in 2013)
-- Reported sales increased 3% to $701 million. Sales grew organically by
2%, and changes in foreign currency exchange ... read more